Welcome to BioSeeker Group!

Triple Analysis: Breast Cancer, Pancreatic Cancer and Cancer Vaccines

Additional Information

Published Date Mar 19, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 3865
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Breast Cancer, Pancreatic Cancer and Cancer Vaccines in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Pancreatic Cancer and by the mechanism/target/effect of Cancer Vaccines.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Breast Cancer, Pancreatic Cancer and Cancer Vaccines.

    To find out more about Triple Analysis: Breast Cancer, Pancreatic Cancer and Cancer Vaccines, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Breast Cancer, Pancreatic Cancer and Cancer Vaccines is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Pancreatic Cancer and by the mechanism/target/effect of Cancer Vaccines. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Breast Cancer
The breast cancer drug report part comprises defined and up to date development strategies for 470 drugs within the portfolio of 247 companies world-wide, from Ceased to Marketed. The report extensively analyses their 234 identified drug targets, organized into 223 drug target strategies, and assesses them in breast cancer drug development.
This part is based on the following publication:
Commercializing Breast Cancer Drugs: The Faster Route to Consider Your Options and Position of Others

Part II: Pancreatic Cancer
The pancreatic cancer report part comprises defined and up to date development strategies for 247 pancreatic cancer drugs within the portfolio of 158 investigators, from Ceased to Marketed. This part extensively analyses their 197 identified drug targets, organized into 163 drug target strategies, and assesses them in eight different compound strategies.
This part is based on the following publication:
Commercializing Pancreatic Cancer Drugs: The Faster Route to Consider Your Options and Position of Others

Part III: Cancer Vaccines
The cancer vaccine drug report part comprises defined and up to date development strategies for 196 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 137 identified drug targets, organized into 114 drug target strategies, and assesses them in 52 cancer indications.
This part is based on the following publication:
Cancer Vaccines: From First-in-Class to Best-in-Class?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Breast Cancer
5.1 The Scope of this Report 32
6 Consider the Therapeutic Target Among Breast Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (234 Drug Targets) 36-522
7 Emerging New Products to Established Ones: Drug Target Strategies of Breast Cancer Drugs by their Highest Stage of Development (223 Drug Target Strategies and 470 Drugs) 523-797
8 Compound Strategies at Work: Competitive Benchmarking of Breast Cancer Drugs by Compound Strategy (8 Compound Strategies) 798-850
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Breast Cancer Drug Pipeline by Investigator (247 Investigators and 470 Drugs) 851-1723
10 Disclaimer 1724
Figures: Includes 8 Figures
Tables: Includes 309 Tables
Total Number of Pages: 1,755

Part II: Pancreatic Cancer
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Pancreatic Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (197 Drug Targets) 31-422
7 Emerging New Products to Established Ones: Drug Target Strategies of Pancreatic Cancer Drugs by their Highest Stage of Development (163 Drug Target Strategies and 247 Drugs) 423-612
8 Compound Strategies at Work: Competitive Benchmarking of Pancreatic Cancer Drugs by Compound Strategy (8 Compound Strategies) 613-651
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Pancreatic Cancer Drug Pipeline by Investigator (158 Investigators and 247 Drugs) 652-1088
10 Drug Index 1091
11 Company Index 1098
Figures: Includes 7 Figures
Tables: Includes 218 Tables
Total Number of Pages: 1,103

Part III: Cancer Vaccines
5.1 The Scope of this Report 28
6 Consider the Therapeutic Target Among Cancer Vaccine Drugs for the Highest Therapeutic Outcome and Return on Investment (137 Drug Targets) 32-245
7 First-in-Class and Me-too Analysis of Cancer Vaccine Drugs (114 Drug Target Strategies and 196 Drugs) 246-262
8 Is First-in-Class the Best-in-Class? 263-386
9 Compound Strategies at Work: Competitive Benchmarking of Cancer Vaccine Drugs by Compound Strategy (7 Compound Strategies) 387-413
10 The Competition Through Close Mechanistic Approximation of Cancer Vaccine Drugs 414-416
11 Selecting Indications for Cancer Vaccine Drugs (52 Cancer Indications) 417-492
12 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Vaccine Drug Pipeline by Company (114 Companies and 196 Drugs) 493-993
13 Disclaimer 994
Figures: Includes 5 Figures
Tables: Includes 239 Tables
Total Number of Pages: 1,007

This Report Includes the Following Companies:
A&G Pharmaceutical
AB Science
Abbott
Abiogen
AC Immune
Access
Active Biotech
Adaptimmune
Adherex
Advanomics
Advantagene
Advaxis
AEgera
AEterna Zentaris
Affibody
Affimed Therapeutics
Agenus
Aida Pharmaceuticals
Alchemia
Alethia Biotherapeutics
Allos Therapeutics
Alnis Biosciences
AlphaVax
Alseres Pharmaceuticals
Amgen
AngioChem
Antisense Pharma
Antisoma
Anza Therapeutics
Aphios
Apogee Biotechnology
Apotex
Ardea Biosciences
Argos Therapeutics
Ariad
ArQule
Array BioPharma
Ascend Therapeutics
Ascepion Pharmaceuticals
Astellas
Astex Pharmaceuticals
AstraZeneca
Attenuon
AVEO
AVI BioPharma
Basilea Pharmaceutica
Bavarian Nordic
Bayer
Bellicum Pharmaceuticals
Beta Pharma
Betagenon
Betapharma
Biogen Idec
BioMarin
Bionovo
BioNTech
BioNumerik
BioSante
Biostar
Biotecnol
BioVex
Boehringer Ingelheim
BreakThrough Therapeutics
Bristol-Myers Squibb
BTG
Calando Pharmaceuticals
Callisto Pharmaceuticals
Cancer Advances
Cancer Research Technology
Cel-Sci
Celera
Celgene
Cell Therapeutics
Celldex Therapeutics
Celltrion
Celsion
Celtic Pharma
Center of Molecular Immunology
CG Therapeutics
Chemokine Therapeutics
Chiesi
Chong Kun Dang
CompleGen
Cornerstone Pharmaceuticals
Cosmo Pharmaceuticals
CreaGene
CritiTech
CSL
Curaxis
CureVac
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytokinetics
CytRx
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Debiopharm
Dendreon
DeveloGen
Domainex
Dong-A
Dongkook Pharm
Douglas
ECI
EGEN Inc
Eisai
Elara Pharmaceuticals
ElexoPharm
Eli Lilly
Endoceutics
Enkam Pharmaceuticals
EntreMed
Enzon
Epeius Biotechnologies
EpiCept
Epizyme
Esperance Pharmaceuticals
Etubics
Eucodis
Exelixis
Expression Drug Designs
FibroGen
Formula Pharmaceuticals
Fresenius
Galectin Therapeutics
Galena Biopharma
Genentech
Generex
Genmab
GenOdyssee Pharmaceuticals
Genta
Genticel
GenVec
Geron
Gilead Sciences
GlaxoSmithKline
Gliknik
GlobeImmune
GlycoGenesys
GlyTag
Got-a-Gene
Gradalis
Harbor BioSciences
Heat Biologics
Heidelberg Pharma
Hemispherx Biopharma
Hoffmann-La Roche
Hospira
Human Genome Sciences
Ichor Medical Systems
Idera Pharmaceuticals
immatics biotechnologies
ImmunoCellular Therapeutics
Immunocore
ImmunoFrontier
ImmunoGen
Immunomedics
Immunotope
Immunovaccine
ImmuPharma
Immutep
Incyte Corporation
Inex
Infinity Pharmaceuticals
Innate Pharma
InNexus Biotechnology
Innovive
Inovio
Insmed
Insys Therapeutics
Intarcia Therapeutics
Intezyne Technologies
Intracel
Intradigm
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Isis Pharmaceuticals
Jennerex Biotherapeutics
Jina Pharmaceuticals
Johnson & Johnson
Kadmon
KAEL-GemVax
Kiadis
Kinex
Kyowa Hakko Kirin
Leo
Ligand
Lipotek
Lorus Therapeutics
MacroGenics
Mannkind
Marillion Pharmaceuticals
Marina Biotech
MBiotec
Meda
Medarex
MediGene
MedImmune
Mediolanum
Medisyn Technologies
Menarini
Merck & Co
Merck KGaA
Merrimack
Mersana Therapeutics
MetaMol Theranostics
MethylGene
Micromet
MolMed
Mologen
Momotaro-Gene
Nektar Therapeutics
Nemod Biotherapeutics
Neovacs
Nereus Pharmaceuticals
Neurocrine Biosciences
NexGenix Pharmaceuticals
Nidus Laboratories
NIH
Nimbus Discovery
Nippon Kayaku
Nippon Shinyaku
Non-industrial source
Northwest Biotherapeutics
Novacea
NovaLead
Novartis
NovaRx
Novogen
Oasmia
OncoGenex Pharmaceuticals
Oncolix
OncoMed
OncoMune
Onconova
OncoTherapy Science
Oncothyreon
Oncovir
Oncozyme Pharma
Onyvax
Orchestra Therapeutics
Orion Pharma
OSI Pharmaceuticals
Oxford BioMedica
OXiGENE
Pacific Biotech
Paladin Labs
PanaGin
Pantarhei Bioscience
Patrys
Pepscan Therapeutics
Peptagen
Peregrine Pharmaceuticals
Pfizer
Pharmacyclics
PharmaForm
PharmaGap
PharmaMar
Pharmexa
PheneX
Philogen
Pierre Fabre
Piramal
Progenics Pharmaceuticals
ProMetic Life Sciences
ProStrakan
Protgen
Protherics
PTC Therapeutics
R&R
Radient Pharmaceuticals
Raptor Pharmaceutical
Ras Therapeutics
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Regulon
responsif
RESprotect
Rexahn
Rigel
Rottapharm Madaus
Samyang
Sanofi
Santaris Pharma
Sarepta Therapeutics
Sareum
Savient Pharmaceuticals
Scancell
Schering-Plough
SEEK
Selvita
Semafore Pharmaceuticals
Shenogen
Shionogi
Shire
Sigma-Tau
Sirnaomics
SRI International
Sun Pharma Advanced Research
SuperGen
Supratek Pharma
Synageva BioPharma
Synta Pharmaceuticals
Taiho
Taiwan Liposome Company
Takeda
Talon Therapeutics
Tapestry Pharmaceuticals
TapImmune
Targa Therapeutics
Tau Therapeutics
Taxolog
Telik
Teva
Thallion Pharmaceuticals
Therion Biologics
Titan Pharmaceuticals
to-BBB
TopoTarget
Tragara Pharmaceuticals
Transgene
Trion Pharma
UMN Pharma
United Biomedical
Vaccinex
Vaxil BioTherapeutics
Vaximm
Vaxon Biotech
VaxOnco
Vectura
Verastem
Vernalis
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest
Viragen
Virionics
ViroMed
ViroTarg
Wyeth
Xerion
Xoma
Yakult Honsha
YM BioSciences
Zensun
Zeria
Zydus Cadila
A Shortlist of Drugs Included are:
177-Lu-AMBA
17ß-hydroxysteroid dehydrogenase-1 inhibitors
2-methoxyestradiol
2aG4-IL-2 fus protein + PS MAb
4-hydroxytamoxifen
5-FU
852A
9-aminocamptothecin
AB-16B5
abagovomab
abiraterone acetate
ABT-510
ACC inhibitor
acolbifene
adecatumumab
aderbasib
Adva-27a
ADXS11-001
AE-37
AEE-788
AEG-35156
AEZS-108
afatinib
aflibercept
AFM-21
AG-1
agatolimod
aglycon protopanaxadiol
AGS-003
AGS-1C4D4
alvespimycin hydrochloride
alvocidib
amatuximab
AMG-386
amonafide dihydrochloride
amonafide malate
amrubicin hydrochloride
amuvatinib
anastrozole
androgen receptor antagonist
angiopep+paclitaxel
Angiozyme
annamycin
anti-C35 MAb
anti-HER-2/neu antisense
anti-HER2 MAb
anti-HER2neu scFv
anti-Hsp90-alpha MAbs
anti-PCDGF MAbs
anticancers
antiestrogen
ANZ-207
apricoxib
AR-002
AR-004
AR-7BD-33-11A
ARC-100
ARQ-197
ARQ-621
ARRY-380
arzoxifene hydrochloride
AS-1402
ASP-08126
astuprotimut-r
atamestane
ATN-224
atrasentan
Auto TAG vaccine
AUY-922
AVE-1642
AVI-4126
avorelin
AVX-701
axitinib
AZD-1480
AZD-4547
AZD-4877
AZD-4992
AZD-8931
BAL-27862
banoxantrone
bardoxolone methyl
becatecarin
belagenpumatucel-L
belinostat
bevacizumab
BEZ-235
BGT-226
BIW-8556
BMN-673
BMS-599626
BMS-690514
BMS-753493
BMS-754807
BN-107
bortezomib
bosutinib
BP-GMAX-CD1
brca2
breast cancer therapy
breast cancer vaccine
BreMel/TNF-alpha
BrevaRex MAb
brivanib alaninate
brivudine
BV-NSCLC-001
BZL-101
CAB-051
Cabozantinib
cancer therapy (1)
cancer therapy (2)
canertinib dihydrochloride
canfosfamide hydrochloride
capecitabine
carbetocin
catumaxomab
CB-10-01
CDX-1307
CEA cancer vaccine
cediranib
celecoxib
cetuximab
CG-201
CGX-0682
CH-4986399
CHF-4227
cilengitide
cixutumumab
clofarabine
CNF-2024
conatumumab
contusugene ladenovec
CP-724714
CPI-613
CreaVax-PC
CRLX-101
crolibulin
CTCE-9908
CTP-37
CUDC-101
custirsen
CV-9103
CV-9201
CVac
CX-4945
CYN-101
D-3263
dabigatran etexilate
dalotuzumab
dasatinib
daunorubicin
DCVax-prostate
denosumab
Diflomotecan
dinaciclib
docetaxel
docetaxel (1)
docetaxel (2)
docetaxel (3)
docetaxel (4)
docetaxel (5)
docetaxel MAb
dovitinib lactate
doxifluridine
doxorubicin
doxorubicin (1)
doxorubicin (10)
doxorubicin (11)
doxorubicin (2)
doxorubicin (3)
doxorubicin (4)
doxorubicin (5)
doxorubicin (6)
doxorubicin (7)
doxorubicin (8)
doxorubicin (9)
doxorubicin citrate
DXL-702
E-75
E-7820
E39
ECI-301
elomotecan
elsamitrucin
emepepimut-S
endostatin
endoxifen
eniluracil
entinostat
enzastaurin hydrochloride
EP-100
epirubicin
epothilone D
erlotinib
ERR antagonists
ertumaxomab
estetrol
estrogen inhibitors
everolimus
exatecan mesylate
exemestane
Exherin
exisulind
EZH2
F16-IL2
fadrozole
FASN inhibitors
figitumumab
flt-4 kinase inhibitors
formestane (1)
formestane (2)
fosfluridine tidoxil
FPI-01
fulvestrant
fusion toxins
Galactomycin-UCLT
galarubicin hydrochloride
ganitumab
gataparsen
GDC-0980
gefitinib
GI-4000
gimatecan
glembatumumab vedotin
GlyB4
golnerminogene pradenovec
goserelin
goserelin acetate ER
GPR40 antagonists
GSK-1059615
GSK-1120212
GSK-2130579A
GSK-2302024A
GV-1001
GVAX
GVX-3322
HAS2 inhibitor
HE-3235
Her-2/Neu peptides
HER2 vaccine
her2/neu antigen
Her2/neu gene therapy
Hi-8 MEL
HS-110
huBrE-3 tiuxetan
HuMax-Her2
HuMax-VEGF
icotinib hydrochloride
icrucumab
ICT-107
idronoxil
IGF-1 receptor inhibitor
IGN-101
IKKe/TBK1 inhibitor
imatinib mesilate
imetelstat
IMGN-388
imMucin
immunogene therapy
IMO-2055
IMP-321
Imuteran
INCB-028060
indisulam
ING-1
ingenol mebutate
INGN-225
INGN-241
inherbins
iniparib
INNO-206
interferon (ß1a)
interleukin-12
interleukins
IPH-3102
ipilimumab
IPP-204106
irinotecan
irinotecan hydrochloride
irosustat
ISA-P53-01
ispinesib mesylate
JMR-132
JX-594
KD032
KW-2170
KX2-391
L19-IL2
labetuzumab
labetuzumab-SN-38
lapatinib ditosylate
lapuleucel-T
larotaxel
lasofoxifene
lenvatinib
leptin antagonists
lestaurtinib
letrozole
leucine-doxorubicin
leuprorelin
linifanib
linsitinib
LipoVIL12
lonafarnib
lonaprisan
LOR-2040
Lovaxin B
LY-2157299
MAGH-22
masitinib
MDX-1140
MDX-1379
ME-103
MEDI-547
Mesd-based peptides
MetXia
MGN-1601
MGN-1703
milataxel
mitoxantrone
MK-2206
MKC-1
MLN-8237
MM-111
MM-121
mocetinostat
MORAb-004
motesanib diphosphate
motexafin gadolinium
MP-529
MS-209
MT-110
MUC-1 vaccine
MVA-BN Her-2 vaccine
Nab-docetaxel
nadroparin
neratinib
nimotuzumab
NK-012
NL-0031
nolatrexed dihydrochloride
NXD-30001
OB-cadherin antibodies
oblimersen sodium
OCM-111
OCM-8054
OCM-8224
OGX-225
OGX-427
olaparib
ON-01910
ON-045270
onartuzumab
Onco-L TCS
oncolytic viruses
OncoVAX
Onyvax-105
OSI-7904L
osteolytic disease therapy
Osteopontin-c inhibitor


OTS-102
P-276-00
p.DOM-WT1-37/p.DOM-WT1-126 DNA
P276-00
paclitaxel
paclitaxel (1)
paclitaxel (10)
paclitaxel (11)
paclitaxel (12)
paclitaxel (13)
paclitaxel (14)
paclitaxel (2)
paclitaxel (3)
paclitaxel (4)
paclitaxel (5)
paclitaxel (6)
paclitaxel (7)
paclitaxel (8)
paclitaxel (9)
paclitaxel polyglumex
paclitaxel-DHA
PancAtak
PankoPep
panobinostat
PANVAC-VF
pasireotide
pasireotide LAR
patupilone
pazopanib hydrochloride
PCI-27483
PD-0325901
PD-0332991
pelitinib
pemetrexed disodium
pentamidine isethionate
peptidomimetics
perifosine
pertuzumab
PhG-alpha-1
pixantrone
PKI-179
PKI-587
plitidepsin
poly-ICLC
polyclonal antibody stimulator
pralatrexate
Prolanta
Prolanta ER
prostate cancer therapy
PROSTVAC
PRX-321
PSK-3668
PSMA ADC
PTC-299
PX-104.1
PX-12
R-763
radiotherapeutic
raloxifene hydrochloride
ramucirumab
retaspimycin
Reximmune-C
Rexin-G
RG-1507
RG-7321
rhErbB3-f
ridaforolimus
rindopepimut
rinfabate
rintatolimod
romidepsin
RR-310
rubitecan
RX-0201
S-488410
S1P3 inhibitor
sabarubicin
sagopilone
SAR-566658
saracatinib
SBC-202
Sch-57050
SCIB-1
SEL-24-1
seliciclib
selumetinib
semaxanib
seocalcitol
SERM + toxin
SF-1126
siltuximab
simotaxel
sipuleucel-T
siRNA gp96 therapy
SM3
SN-38 (1)
SN-38 (2)
SNG-163
SNG-8023
SNG-8038
sorafenib tosylate
SPC-2968
SR-13668
SR-16157
SR-31747
ß-lapachone
STA-9090
steroid sulfatase inhibitor
STP-503
SU-14813
SU-6668
sunitinib malate
Survivac
survivin-2B
Symadex
talminogene laherparepvec
tamoxifen (1)
tamoxifen (2)
tamoxifen, oral liquid
tanespimycin
tariquidar
TAS-108
tegafur + uracil
telomerase vaccine
temsirolimus
Tenarad
TG-4010
thiocoraline
thymalfasin
thymectacin
tigatuzumab
tipapkinogene sovacivec
tipifarnib
tivozanib
TLK-58130
TLN-4601
TNF + paclitaxel
TNF-alpha
tocilizumab
toremifene citrate
trabedersen
trastuzumab
trastuzumab (1)
trastuzumab (2)
trastuzumab (3)
trastuzumab emtansine
trastuzumab-MMAE conjugate
tremelimumab
triapine
triciribine phosphate
trilostane
triptorelin pamoate
TroVax
TS-1
TTL-2019
TTL-3101
tucotuzumab celmoleukin
UCN-01
V-930
V935
vandetanib
varlitinib
vatalanib
velimogene aliplasmid
veliparib
verpasep caltespen
vismodegib
vitespen
VM-206
volociximab
VS-4718
VS-507
VS-5095
VX-001
WX-671
WX-UK1
XL-147
XL-647
XL-765
Y-90-labetuzumab
YM-155
Z-360
Zemab
zibotentan
ZYC-300

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Breast Cancer, Pancreatic Cancer and Cancer Vaccines.
    To find out more about Triple Analysis: Breast Cancer, Pancreatic Cancer and Cancer Vaccines, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Breast Cancer, Pancreatic Cancer and Cancer Vaccines is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Lung Cancer, Protein Kinase Inhibitors and Antibodies
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Lung Cancer), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Antibodies). Learn More


Triple Analysis: Breast Cancer, Lung Cancer and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Lung Cancer and by the mechanism/target/effect of Protein Kinase Inhibitors. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Colorectal Cancer, Prostate Cancer and Peptides
This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Prostate Cancer and by the compound strategy of Peptides. Learn More


Triple Analysis: Breast Cancer, Leukemia and Antibodies
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Leukemia and by the compound strategy of Antibodies. Learn More